49.97USD-0.36%Mkt Cap: 12.59B USDP/E: 16.58Last update: 2026-05-26
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatme…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap12.59B USD
Enterprise Value11.87B USD
Revenue (TTM)2.38B USD
Gross Profit2.24B USD
Net Income (TTM)782.57M USD
Revenue/Share8.915 USD
Last Price49.97 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS30161Q1040
Valuation
P/E (Trailing)16.58
P/E (Forward)12.26
PEG2.56
EV/EBITDA12.04
EV/Revenue5.00
P/S5.25
P/B6.51
EPS (TTM)3.02
EPS (Forward)4.05
52W Range
33.7691% of range51.63
52W High51.63 USD
52W Low33.76 USD
Profitability
Gross Margin96.39%
Oper. Margin41.15%
EBITDA Margin41.50%
Profit Margin33.73%
ROE36.21%
ROA27.51%
Growth
Revenue Growth10.00%
Earnings Growth43.60%
Cash Flow & Leverage
Operating CF884.27M USD
CapEx (TTM)39.93M USD
FCF Margin26.48%
FCF Yield5.00%
Net Debt-607.67M USD
Net Debt/EBITDA-0.62
Balance Sheet
Debt/Equity0.08
Current Ratio3.26
Quick Ratio3.01
Book Value/Sh7.630 USD
Cash/Share3.092 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Target (Mean)49.65 USD
Target Range40.00 USD – 62.00 USD
# Analysts17
Ownership
Shares Out.251.36M
Float206.29M
Insiders1.81%
Institutions107.62%
Short Interest
Short Ratio13.1d
Short % Float16.24%
Short % Out.11.94%
Shares Short30.01M
Short (prev mo.)27.26M
Technical
SMA 5044.98 (+11.1%)
SMA 20042.19 (+18.4%)
Beta0.39
S&P 52W Chg28.31%
Avg Vol (30d)2.68M
Avg Vol (10d)2.59M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—